Quest Diagnostics®

Is it COVID-19, influenza A or B (flu), or something else?

New respiratory tests can help you make a precise diagnosis

It's flu season, but we're also still in the midst of the COVID-19 pandemic. SARS-CoV-2 (COVID-19), influenza A or B (flu), and other respiratory infections can present with similar symptoms such as fever, cough, and shortness of breath.

That's why it's important to consider testing for each of these contagious illnesses at the same time—especially for older adults, pregnant women, and people with underlying conditions or compromised immune systems.

Knowing which infection—or infections—are causing your patient's symptoms will help you make the best treatment decisions.

New co-testing options with Quest

Our new testing options use a single specimen to co-test for SARS-CoV-2 and other respiratory pathogens, which helps expedite diagnosis so you can develop an appropriate treatment/care plan.

Visit QuestDiagnostics.com/Covid-19/HCP to learn more

Whether caused by COVID-19, influenza, or another respiratory illness, the symptoms can be very similar[1]:

- Fever or feeling feverish/chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue (tiredness)
- Sore throat
- Runny or stuffy nose
- Muscle pain or body aches
- Headache
- Some people may have vomiting and diarrhea, though this is more common in children than adults

During widespread circulation of SARS-CoV-2 and influenza, **clinicians should consider testing patients with compatible symptoms for both viruses, according to the CDC.[2]**

For more information, call your sales representative or **1.866.MY.QUEST (1.866.697.8378)**

Identifying the source of infection is the first step in managing patient treatment

Quest Diagnostics offers the convenience of co-testing for influenza A and B and other respiratory pathogens in conjunction with testing for SARS-CoV-2.

Panels for respiratory pathogen testing	Test code	CPT code(s)*
NEW: SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	31688	87636
NEW: SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	31687	87635 (HCPCS: U0003), 87633, 87486, 87581
NEW: SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	31686	87635 (HCPCS: U0003), 87633
Influenza A and B RNA, Qualitative Real-Time PCR	16086	87502
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635 (HCPCS:U0003)
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR	91989	87631
Respiratory Pathogen Panel	37444	87633, 87486 (*C. pneumoniae*), 87581 (*M. pneumoniae*)
Respiratory Viral Panel, PCR	95512	87633

*CPT codes are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Visit our test directory to learn more about our complete portfolio of respiratory infection tests

You can count on Quest Diagnostics to help you get the **right test for the right patient for faster diagnosis and treatment**

Leadership

A diagnostic leader during global health crises, Quest introduced a COVID-19 test 2 days before the virus was labeled a worldwide pandemic. Our 47,000 passionate employees continue to deliver diagnostic insights to support the effort to fight COVID-19.

Convenience

Labs available nationwide to support increased testing volume including blood specimen collection in over 2,250 Patient Service Centers; integration with most EHRs through Quanum® Lab Services Manager.

History and expertise

Four decades of experience leading infectious disease testing during public health emergencies, and hundreds of experts available to help interpret test results.

Contact your Quest Diagnostics sales representative at **1.866.MY.QUEST (1.866.697.8378)**

- The cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests ("Tests") have not been FDA cleared or approved.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. The Roche test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Reference:
1. Centers for Disease Control and Prevention (CDC). Similarities and differences between flu and COVID-19. Reviewed August 31, 2020. Accessed September 24, 2020. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
2. Centers for Disease Control and Prevention (CDC). Ten clinical tips on COVID-19 for healthcare providers involved in patient care. Updated September 16, 2020. Accessed September 24, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-tips-for-healthcare-providers.html

Image content used for illustrative purposes only. Persons depicted in the content are models.

QuestDiagnostics.com

Quest Diagnostics®